OKYO Pharma's Non-Executive Director purchased 5,000 shares, increasing his total to 35,201 shares.
Quiver AI Summary
OKYO Pharma Limited, a biopharmaceutical company focused on developing therapies for neuropathic corneal pain and anterior segment eye diseases, announced that Non-Executive Director John Brancaccio has acquired an additional 5,000 shares at $1.48 each, increasing his total holdings to 35,201 shares. The company is set to begin a global Phase 3 clinical trial later this year, aiming to enroll around 111 patients to test a single-dose regimen of urcosimod for treating neuropathic corneal pain. For more details, visit their website or contact their investor relations.
Potential Positives
- John Brancaccio, Non-Executive Director, demonstrates confidence in the company by purchasing 5,000 shares, increasing his stake to 35,201 shares.
- OKYO Pharma is set to initiate a global Phase 3 pivotal clinical trial for its investigational therapy, signaling progress in its drug development pipeline.
- The upcoming clinical trial aims to evaluate a treatment for neuropathic corneal pain, addressing an unmet medical need in the ophthalmic field.
Potential Negatives
- The press release does not provide any information regarding the current progress or outcomes of existing clinical trials, leaving stakeholders uncertain about the efficacy of the company's therapies.
- The company has not disclosed any financial results or funding statuses, which could raise concerns about its financial health and ability to sustain ongoing research and development efforts.
- The announcement of a future clinical trial without detailed timelines or information on regulatory approval processes may indicate potential delays or uncertainties in the company’s research pipeline.
FAQ
What is OKYO Pharma known for?
OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
Who recently purchased shares in OKYO Pharma?
John Brancaccio, OKYO Pharma’s Non-Executive Director, purchased 5,000 ordinary shares recently.
What is the current share price for OKYO Pharma?
The current share price for OKYO Pharma is $1.48 per share.
What clinical trial is OKYO Pharma planning?
OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial for urcosimod in the second half of 2026.
How many patients will be enrolled in the clinical trial?
Approximately 111 patients will be enrolled in the clinical trial evaluating urcosimod for neuropathic corneal pain.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OKYO Hedge Fund Activity
We have seen 6 institutional investors add shares of $OKYO stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 3,652,190 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,880,025
- MAVEN SECURITIES LTD added 1,175,535 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,892,611
- STONEPINE CAPITAL MANAGEMENT, LLC added 850,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,368,500
- BALYASNY ASSET MANAGEMENT L.P. added 584,796 shares (+inf%) to their portfolio in Q1 2026, for an estimated $941,521
- DAUNTLESS INVESTMENT GROUP, LLC removed 467,704 shares (-99.2%) from their portfolio in Q1 2026, for an estimated $753,003
- RENAISSANCE TECHNOLOGIES LLC removed 138,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $222,180
- UBS GROUP AG added 57,588 shares (+2651.4%) to their portfolio in Q1 2026, for an estimated $92,716
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OKYO Analyst Ratings
Wall Street analysts have issued reports on $OKYO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/20/2026
To track analyst ratings and price targets for $OKYO, check out Quiver Quantitative's $OKYO forecast page.
Full Release
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
For further information, please visit www.okyopharma.com .
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email:
[email protected]
